Introduction
============

Ovarian cancer is identified as the seventh most commonly diagnosed carcinoma in the world and the fifth leading cause of carcinoma-related death in women [@B1]-[@B2]. Because of the lack of screening for diagnosis of ovarian cancer at early stage, approximately 85 percent of cases of ovarian cancer are diagnosed at an advanced stage (III/IV) [@B3]. Patients with ovarian cancer face with worse prognosis that the 5-year survival rate is only 30% [@B4]. Several factors are correlated with the survival of ovarian cancer, including FIGO stage, residual disease, and grade of differentiation [@B5]-[@B7]. Nevertheless, patients with the similar FIGO stage and grade have different prognosis. Therefore, it is imperative to identify accurate, inexpensive and reproducible prognosis factors of ovarian cancer.

Some studies have suggested the relationship between the ABO blood type and the risk of various carcinomas, including colorectal cancer, renal cell carcinoma, and pancreatic carcinoma [@B8]-[@B10]. Meanwhile, in a recent analysis of 49,153 women in 1 prospective study, individuals with presence of the B antigen (B/AB) had an increased incidence of ovarian cancer compared with those with non-B antigen (A/O) [@B11]. While several retrospective studies have showed that blood type A was correlated with a higher incidence of ovarian carcinoma compared with blood type O [@B12]-[@B14]. However, few studies have evaluated the association between ABO blood group and the prognosis among patients with ovarian cancer. Two retrospective researches reported that blood type A was correlated with a worse clinical outcome in 256 patients with ovarian cancer and in 92 patients with ovarian cancer [@B15]-[@B16]. Therefore, we aimed to evaluate the relationship between ABO blood group and the survival of patients with ovarian carcinoma.

Materials and Methods
=====================

Patient selection
-----------------

941 patients who were newly diagnosed with primary ovarian carcinoma from February 2007 to February 2016 at the Zhejiang Cancer Hospital were selected for this retrospective research. The diagnosis of ovarian carcinoma was confirmed by a postoperative pathology diagnosis. The criteria of pathology diagnosis were in accordance with the World Health Organization classification standard. The inclusive criteria as follows: (1) ovarian cancer was pathologically confirmed; (2) complete clinical records, including age, FIGO stage, histologic differentiation, menopause, family history of cancer, ascites at surgery, residual disease, and follow-up data; (3) sufficient clinical examination, including ABO blood group, preoperative serum CA125 level. The ABO blood type (A/B/AB/O) was checked by anti-A and anti-B blood grouping reagents (monoclonal antibody). CA125 antigen was quantified in serum in Zhejiang cancer hospital using chemiluminescence microparticle immune assay (CMIA) \[ARCHITECT CA125 II Reagent Kit, Abbott\]. In the first half year undergoing surgery, patients were followed up at the first, third and sixth months. Patients were followed up every six months during the following years. The follow up examinations include physical examination, serum CA125 level and blood routine examination el at. This retrospective study was approved by the Ethics Committee of Zhejiang Cancer Hospital. All patients provided written informed consent.

Statistical analysis
--------------------

The relationship between ABO blood type and clinical features in patients with ovarian carcinoma was analyzed using chi-square tests. The relationship between presence of B antigen (B/AB) and clinical features in patients with ovarian cancer was also evaluated using chi-square tests. Overall survival (OS) was calculated using the Kaplan-Meier method and the log-rank test. Hazard ratio and 95% confidence interval were calculated using COX regression analyses. The overall survival curve was evaluated by GraphPad Prism 7 software. All data were examined by the SPSS software (version 19.0). A value of P \< 0.05 was regarded as statistical significance.

Results
=======

Patient characteristics
-----------------------

We enrolled 941 patients with ovarian cancer in the study from February 2007 to February 2016. The median age of all individuals was 54 years (range: 23-81 years). 51 patients had FIGO stage I, 76 patients had FIGO stage II, 651 patients had FIGO stage III, and 163 patients had FIGO stage IV. A total of 795 patients had serous cancer, and 146 patients had other. 322 patients had blood type A (34.2%), 250 patients had blood type B (26.6%), 75 patients had blood type AB (8.0%), and 294 patients had blood type O (31.2%). No significant association was determined between the ABO blood group and age, menopause, FIGO stage, family history of cancer, ascites at surgery, residual disease, histology, grade, lymph node stats, Rh factor, and CA125 at diagnosis (Table [1](#T1){ref-type="table"}).

Correlation between presence of the B antigen (B/AB) and clinical features
--------------------------------------------------------------------------

The correlation between presence of the B antigen (B/AB) and clinical characteristics was listed in Table [2](#T2){ref-type="table"}. 325 patients had presence of the B antigen (B/AB) (34.5%), and 616 patients had presence of the non-B antigen (A/O) (65.5%). None of the clinical features was significantly correlated with presence of the B antigen (B/AB), including age, menopause, FIGO stage, family history of cancer, ascites at surgery, residual disease, histology, lymph node stats, Rh factor, and CA125 at diagnosis. Nevertheless, presence of the B antigen (B/AB) was notably associated with grade (P=0.027).

Prognostic variables for OS
---------------------------

The Kaplan-Meier curves suggested that patients in blood type B had a worse survival compared with those in the non-B blood types (P=0.048) (Figure [1](#F1){ref-type="fig"}). Furthermore, we evaluated the prognostic value of the ABO blood group with presence of the B antigen (B/AB) and non-B antigen (A/O), patients with presence of the B antigen (B/AB) had a worse survival compared to the patients with presence of the non-B antigen (A/O) (P=0.010) (Figure [2](#F2){ref-type="fig"}).

Univariate analysis indicated that in addition to presence of the B antigen (B/AB) (P=0.011), menopause (P=0.028), FIGO stage I (P=0.008), FIGO stage II (P=0.005), ascites at surgery (P=0.006), residual disease (P=0.008), and lymph node stats (P=0.022) were also significantly correlated with OS. In the multivariate analysis, menopause (P=0.010), FIGO stage I (P=0.008), FIGO stage II (P=0.027), presence of the B antigen (B/AB) (P=0.009) were significantly associated with OS (Table [3](#T3){ref-type="table"}).

Subgroup analysis according to FIGO stage and menopause
-------------------------------------------------------

To evaluate the subgroups of ovarian cancer affected by presence of the B antigen (B/AB), we classified patients based on FIGO stage (I, n=51; II, n=76; III, n=651; IV, n=163) and menopause (Yes, n=542; No, n=399). OS of FIGO stage I and IV were significantly worse for patients with presence of the B antigen (B/AB) (P=0.009 and P=0.035), but OS did not differ neither FIGO stage II nor III (P=0.279 and P=0.219) (Figure [3](#F3){ref-type="fig"}). OS of patients with menopause was notably worse for patients with presence of the B antigen (B/AB) (P=0.035), but OS of patients without menopause did not differ (P=0.119) (Figure [4](#F4){ref-type="fig"}).

Discussions
===========

In this large, retrospective study, blood groups B and AB were significantly associated with worse survival of ovarian cancer. The magnitude of the relationship was similar for blood group B and AB indicating that the B antigen may affect ovarian progression. In analyses of presence of the B antigen (B/AB) compared with absence of the B antigen (A/O), we observed a significantly worse survival in ovarian cancer with FIGO stage I, IV, and menopause.

Previous studies have suggested that the ABO blood group play an important role in the development of various cancers. As ABO antigens are expressed on the surface of several human tissues and cells, such as the ovary surface epithelial cells and ovarian inclusion cysts [@B17]-[@B18]. The relationship between the ABO blood group and the cancer risk has been intensely investigated across many different types of cancer, including pancreatic carcinoma, nasopharyngeal cancer, gastric carcinoma, lung carcinoma [@B19]-[@B22]. Besides, in a large, prospective study of women, individuals with presence of the B antigen (B/AB) were associated with increased risk of ovarian cancer [@B11]. However, previous retrospective studies have suggested that blood type A had an increased incidence of ovarian cancer [@B12]-[@B14]. Proposed reasons for these inconsistent findings were that participants in all studies were from different races, most retrospective reports did not adjust for other possible confounders, and several studies used hospital-based control individual, which may not represent the ABO distribution in the general population [@B12]-[@B13].

There are also many studies have suggested a possible association between the ABO blood group and the clinical outcome in patients with malignant cancers. In 900 patients who underwent resection for renal cell carcinoma, the authors revealed that the non-O blood type was significantly associated with decreased OS [@B23]. Previous study about 404 patients undergoing resection for esophageal carcinoma, there was no relationship between the ABO blood type and the prognosis of esophageal cancer [@B24]. One study showed that blood group A and AB had a shorter OS than others in 333 patients undergoing resection for non-small cell lung cancer [@B25]. Meanwhile, two retrospective reports with a relatively small number of individuals enrolled, regarding the association between the ABO blood group and the clinical outcome of patients with ovarian cancer. Their findings suggested that a negative relationship between blood type A and ovarian cancer survival, but no relationship with blood type B [@B15]-[@B16]. Owing to these results, we hypothesized that whether blood type A or blood type B might associate with prognosis of ovarian cancer. We found that blood group B and AB indicated worse survival in patients with ovarian cancer, especially in patients with FIGO I, IV, and menopause. The reasons for these conflicting results were that a relatively large number of participants enrolled without exclusion of FIGO stage IV, the proportions of ABO blood group were different. 256 patients with ovarian cancer in previous study, 60 patients had blood group A (23.4%), 52 patients had blood group B (20.3%), 24 patients had blood group AB (9.4%), and 120 patients had blood type O (46.9%) [@B15]. 941 patients enrolled in our study, the ABO distribution was 322 patients with blood type A (34.2%), 250 patients with blood type B (26.6%), 75 patients with blood type AB (8.0%), and 294 patients with blood type O (31.2%).

The mechanisms of the ABO blood group and the survival of cancer have not been intensely investigated. As A and B antigens are also expressed on the ovarian cancer tissues [@B17]-[@B18]. We hypothesized that the ABO antigens in cancer cells contribute to the pathway signaling, intracellular adhesion, and inflammation, all of which play an important part in the progression of carcinoma [@B26]. The expression of ABO blood antigens on tumor cells was influenced by hyper-methylation of ABO promoter, which was associated with the tumor progression. ABO promoter hyper-methylation was also checked in dysplastic and hyperplastic tissues adjacent to tumor, indicating that it was an early event in the development of carcinoma [@B27]. Therefore, B antigen was correlated with the survival of patients in the FIGO stage I. The ABO gene, which is located on chromosome 9q34, encodes glycosyltransferases to form the ABO blood group antigens [@B28]. The ABO gene is one frequent region of deletion in ovarian cancer [@B29]. Aberrant glycosylation was one of the most important hallmarks of tumor [@B30]. Therefore, we speculate that patients with presence of B antigen (B/AB) have more malignant cancer cells. Patients in the FIGO stage IV showed the worse survival.

There are several limitations of this analysis: first, this study was a retrospective and single-center analysis. Second, the clinical results regarding the ABO blood types were determined by a serological technique according to the phenotype, not the genotype. Third, all the participants of this analysis were Chinese, perhaps restricting the generalizability of these findings. Therefore, further investigations are required to clarify the reproducibility of this study, including the multi-center analysis and the investigation of different races from other countries.

In summary, our results show that there are a possible association between the B blood group antigen and worse clinical outcome of ovarian cancer. Patients with presence of the B antigen (B/AB) had a significantly worse survival than those with non-B antigen (A/O), especially in patients with FIGO stage I, IV, and menopause. However, given the inconsistent findings of previous studies, additional investigations are urgently needed to evaluate this association. Researches of potential mechanisms for a relationship between the ABO blood group and ovarian cancer prognosis also are needed.
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###### 

Relationship between ABO blood group and clinicopathological features in patients with ovarian cancer

  Characteristics                   Total (N=941)   A (N=322)    B (N=250)    AB (N=75)    O (N=294)    *P* value
  --------------------------------- --------------- ------------ ------------ ------------ ------------ -----------
  **Age\[median (range),years\]**   54 (23-81)      55 (23-80)   54 (25-80)   55 (36-77)   53 (26-81)   
  ≤55                               503             170          134          38           161          0.920
  \>55                              438             152          116          37           133          
  **Menopause**                                                                                         
  Yes                               542             191          142          47           162          0.574
  No                                399             191          108          28           132          
  **FIGO stage**                                                                                        
  I                                 51              16           17           5            13           0.504
  II                                76              25           18           7            26           
  III                               651             218          184          50           199          
  IV                                163             63           31           13           56           
  **Family history of cancer**                                                                          
  Yes                               307             104          76           29           98           0.595
  No                                634             218          174          46           196          
  **Ascites at surgery**                                                                                
  Yes                               448             164          108          31           145          0.523
  No                                171             63           43           17           48           
  Unkown                            322                                                                 
  **Residual disease**                                                                                  
  ≤1cm                              817             281          215          64           257          0.932
  \>1cm                             124             41           35           11           37           
  **Histology**                                                                                         
  Serous                            795             275          206          65           249          0.725
  Other                             146             47           44           10           45           
  **Grade**                                                                                             
  Well                              363             133          84           26           120          0.286
  Moderate                          223             68           69           22           64           
  Poorly                            253             89           63           18           83           
  Unkown                            102                                                                 
  **Lymph node stats**                                                                                  
  Positive                          532             187          139          38           168          0.683
  Negative                          409             135          111          37           126          
  **Rh factor**                                                                                         
  Positive                          937             319          250          74           294          0.125
  Negative                          4               3            0            1            0            
  **CA125 at diagnosis**                                                                                
  ≤35 U/ml                          55              19           12           5            19           0.851
  \>35 U/ml                         886             303          238          70           275          

FIGO, International Federation of Gynecology and Obstetrics.

###### 

Relationship between B antigen and clinicopathological features in patients with ovarian cancer

  Characteristics                   Non-B antigen (A/O) (N=616)   B antigen (B/AB) (N=325)   *P* value
  --------------------------------- ----------------------------- -------------------------- -----------
  **Age\[median (range),years\]**   54 (23-81)                    55 (25-80)                 
  ≤55                               331                           172                        0.813
  \>55                              285                           153                        
  **Menopause**                                                                              
  Yes                               353                           189                        0.802
  No                                263                           136                        
  **FIGO stage**                                                                             
  I                                 29                            22                         0.092
  II                                51                            25                         
  III                               417                           234                        
  IV                                119                           44                         
  **Family history of cancer**                                                               
  Yes                               202                           105                        0.880
  No                                414                           220                        
  **Ascites at surgery**                                                                     
  Yes                               309                           139                        0.333
  No                                111                           60                         
  Unkown                                                                                     
  **Residual disease**                                                                       
  ≤1cm                              538                           279                        0.520
  \>1cm                             78                            46                         
  **Histology**                                                                              
  Serous                            524                           271                        0.498
  Other                             92                            54                         
  **Grade**                                                                                  
  Well                              253                           110                        **0.027**
  Moderate                          132                           91                         
  Poorly                            172                           81                         
  Unkown                                                                                     
  **Lymph node stats**                                                                       
  Positive                          355                           177                        0.351
  Negative                          261                           148                        
  **Rh factor**                                                                              
  Positive                          613                           324                        0.688
  Negative                          3                             1                          
  **CA125 at diagnosis**                                                                     
  ≤35 U/ml                          38                            17                         0.560
  \>35 U/ml                         578                           308                        

FIGO, International Federation of Gynecology and Obstetrics.

###### 

Overall survival analyses according to ABO blood group in patients with ovarian cancer

  Variables                                           Univariate   Multivariate                                     
  --------------------------------------------------- ------------ -------------- ----------- ------- ------------- -----------
  **Age ( \>55 vs. ≤55)**                             1.200        0.960-1.499    0.109                             
  **Menopause (No vs. Yes)**                          1.288        1.027-1.615    **0.028**   1.530   1.105-2.119   **0.010**
  **FIGO stage**                                                                                                    
  I                                                   0.317        0.135-0.744    **0.008**   0.297   0.121-0.727   **0.008**
  II                                                  0.430        0.239-0.775    **0.005**   0.476   0.247-0.919   **0.027**
  III                                                 1.099        0.796-1.516    0.567       1.121   0.778-1.615   0.541
  IV                                                  1.000                                                         
  **Family history of cancer (No vs. Yes)**           0.845        0.663-1.077    0.173                             
  **Ascites at surgery (No vs. Yes)**                 1.706        1.166-2.497    **0.006**   1.461   0.981-2.175   0.062
  **Residual disease (\>1cm vs. ≤1cm)**               1.454        1.102-1.918    **0.008**   1.163   0.735-1.841   0.519
  **Histology (Other vs. Serous)**                    1.113        0.826-1.500    0.481                             
  **Grade**                                                                                                         
  Well                                                0.830        0.583-1.182    0.302                             
  Moderate                                            1.119        0.862-1.453    0.400                             
  Poorly                                              1.000                                                         
  **Lymph node stats (Negative vs. Positive)**        1.303        1.038-1.635    **0.022**   0.924   0.656-1.301   0.652
  **CA125 at diagnosis (\>35 U/ml vs. ≤35 U/ml)**     1.144        0.669-1.955    0.624                             
  **Blood type**                                                                                                    
  A                                                   0.844        0.633-1.126    0.249                             
  B                                                   1.258        0.947-1.671    0.112                             
  AB                                                  1.147        0.752-1.749    0.524                             
  O                                                   1.000                                                         
  **A antigen \[Absent (O/B) vs.Present (A/AB) \]**   0.807        0.642-1.015    0.067                             
  **B antigen \[Absent (O/A) vs. Present (B/AB)\]**   1.342        1.069-1.685    **0.011**   1.532   1.111-2.112   **0.009**
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